Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

Medications designed to treat diabetes by lowering blood sugar levels, like Ozempic, continue to turn up added benefits, and ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Loss of skeletal muscle mass is a known risk factor for falls. Researchers from the University of Tsukuba conducted a 5-yr follow-up study on 471 patients with type 2 diabetes and found that ...

The study supports prior research that found the same thing.

Research shows diabetes medications may cut Alzheimer's risk by up to 43% in patients with type 2 diabetes, offering ...

Certain diabetes medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, are associated with weight reduction, which may contribute to muscle mass loss and, consequently ...